JP2012502026A - ラクトバチルス属細菌の免疫調節抽出物及びその製造法と使用法 - Google Patents

ラクトバチルス属細菌の免疫調節抽出物及びその製造法と使用法 Download PDF

Info

Publication number: JP2012502026A
Authority: JP; Japan
Prior art keywords: extract; lactobacillus; hours; bacterial; cells
Prior art date: 2008-09-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2011526017A

Other languages

English (en)

Japanese (ja)

Inventor

ジャック，アランボーエル，

マルコサルヴァニ，

ジャン−ピエール，レオンヴィグル，

レティシアレラ，ジゼルシャルヴェ，

カルロシアヴァロリ，

Original Assignee

オーエムファルマ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-04

Filing date

2008-09-04

Publication date

2012-01-26

2008-09-04 Application filed by オーエムファルマ filed Critical オーエムファルマ

2012-01-26 Publication of JP2012502026A publication Critical patent/JP2012502026A/ja

Status Pending legal-status Critical Current

Links

239000000284 extract Substances 0.000 title claims abstract description 305
241000186660 Lactobacillus Species 0.000 title claims abstract description 37
238000004519 manufacturing process Methods 0.000 title abstract description 21
230000004957 immunoregulator effect Effects 0.000 title 1
229940039696 lactobacillus Drugs 0.000 claims abstract description 34
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 16
230000002519 immonomodulatory effect Effects 0.000 claims abstract description 14
235000015872 dietary supplement Nutrition 0.000 claims abstract description 11
230000001580 bacterial effect Effects 0.000 claims description 129
241000186840 Lactobacillus fermentum Species 0.000 claims description 58
229940012969 lactobacillus fermentum Drugs 0.000 claims description 58
238000000034 method Methods 0.000 claims description 47
102000003814 Interleukin-10 Human genes 0.000 claims description 27
108090000174 Interleukin-10 Proteins 0.000 claims description 27
241001465754 Metazoa Species 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 24
210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 21
102000013462 Interleukin-12 Human genes 0.000 claims description 18
108010065805 Interleukin-12 Proteins 0.000 claims description 18
241000218588 Lactobacillus rhamnosus Species 0.000 claims description 18
208000006673 asthma Diseases 0.000 claims description 18
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 17
230000003308 immunostimulating effect Effects 0.000 claims description 16
238000009295 crossflow filtration Methods 0.000 claims description 14
230000008569 process Effects 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 10
238000007385 chemical modification Methods 0.000 claims description 9
208000035475 disorder Diseases 0.000 claims description 9
239000000047 product Substances 0.000 claims description 9
240000006024 Lactobacillus plantarum Species 0.000 claims description 8
235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 8
229940072205 lactobacillus plantarum Drugs 0.000 claims description 8
240000002605 Lactobacillus helveticus Species 0.000 claims description 7
235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 7
241001468157 Lactobacillus johnsonii Species 0.000 claims description 7
210000003979 eosinophil Anatomy 0.000 claims description 7
229940054346 lactobacillus helveticus Drugs 0.000 claims description 7
230000001079 digestive effect Effects 0.000 claims description 6
210000004698 lymphocyte Anatomy 0.000 claims description 6
239000013618 particulate matter Substances 0.000 claims description 6
208000012931 Urologic disease Diseases 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
230000000813 microbial effect Effects 0.000 claims description 5
210000000440 neutrophil Anatomy 0.000 claims description 5
208000014001 urinary system disease Diseases 0.000 claims description 5
206010027654 Allergic conditions Diseases 0.000 claims description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
244000199866 Lactobacillus casei Species 0.000 claims description 4
235000013958 Lactobacillus casei Nutrition 0.000 claims description 4
241000186605 Lactobacillus paracasei Species 0.000 claims description 4
206010035664 Pneumonia Diseases 0.000 claims description 4
235000004279 alanine Nutrition 0.000 claims description 4
229940017800 lactobacillus casei Drugs 0.000 claims description 4
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
201000007094 prostatitis Diseases 0.000 claims description 4
230000002829 reductive effect Effects 0.000 claims description 4
208000023504 respiratory system disease Diseases 0.000 claims description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
239000004475 Arginine Substances 0.000 claims description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
201000008197 Laryngitis Diseases 0.000 claims description 3
206010024971 Lower respiratory tract infections Diseases 0.000 claims description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
239000004472 Lysine Substances 0.000 claims description 3
208000011623 Obstructive Lung disease Diseases 0.000 claims description 3
201000007100 Pharyngitis Diseases 0.000 claims description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
206010044302 Tracheitis Diseases 0.000 claims description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
201000003146 cystitis Diseases 0.000 claims description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
201000009240 nasopharyngitis Diseases 0.000 claims description 3
230000000414 obstructive effect Effects 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000006340 racemization Effects 0.000 claims description 3
201000009890 sinusitis Diseases 0.000 claims description 3
206010044008 tonsillitis Diseases 0.000 claims description 3
201000004813 Bronchopneumonia Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
206010063057 Cystitis noninfective Diseases 0.000 claims description 2
206010012438 Dermatitis atopic Diseases 0.000 claims description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
244000199885 Lactobacillus bulgaricus Species 0.000 claims description 2
235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 2
241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims description 2
241000186604 Lactobacillus reuteri Species 0.000 claims description 2
208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 2
208000000450 Pelvic Pain Diseases 0.000 claims description 2
206010037596 Pyelonephritis Diseases 0.000 claims description 2
206010057190 Respiratory tract infections Diseases 0.000 claims description 2
206010039085 Rhinitis allergic Diseases 0.000 claims description 2
206010048302 Tubulointerstitial nephritis Diseases 0.000 claims description 2
206010046306 Upper respiratory tract infection Diseases 0.000 claims description 2
208000026723 Urinary tract disease Diseases 0.000 claims description 2
230000009798 acute exacerbation Effects 0.000 claims description 2
201000009961 allergic asthma Diseases 0.000 claims description 2
201000010105 allergic rhinitis Diseases 0.000 claims description 2
201000008937 atopic dermatitis Diseases 0.000 claims description 2
201000003139 chronic cystitis Diseases 0.000 claims description 2
208000013507 chronic prostatitis Diseases 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
206010022000 influenza Diseases 0.000 claims description 2
201000006334 interstitial nephritis Diseases 0.000 claims description 2
208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 2
229940001882 lactobacillus reuteri Drugs 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
208000000143 urethritis Diseases 0.000 claims description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
235000003704 aspartic acid Nutrition 0.000 claims 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
235000013922 glutamic acid Nutrition 0.000 claims 2
239000004220 glutamic acid Substances 0.000 claims 2
229930182817 methionine Natural products 0.000 claims 2
208000024891 symptom Diseases 0.000 claims 2
239000003795 chemical substances by application Substances 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 69
208000015181 infectious disease Diseases 0.000 abstract description 18
201000010099 disease Diseases 0.000 abstract description 13
208000023275 Autoimmune disease Diseases 0.000 abstract description 6
206010020751 Hypersensitivity Diseases 0.000 abstract description 6
206010061218 Inflammation Diseases 0.000 abstract description 6
230000002757 inflammatory effect Effects 0.000 abstract description 6
239000002671 adjuvant Substances 0.000 abstract description 5
230000007407 health benefit Effects 0.000 abstract description 5
230000004054 inflammatory process Effects 0.000 abstract description 5
230000007815 allergy Effects 0.000 abstract description 4
230000016396 cytokine production Effects 0.000 abstract description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 87
210000004027 cell Anatomy 0.000 description 87
239000002028 Biomass Substances 0.000 description 64
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 61
241000699670 Mus sp. Species 0.000 description 54
239000000243 solution Substances 0.000 description 43
230000009089 cytolysis Effects 0.000 description 42
238000004090 dissolution Methods 0.000 description 42
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
108020000411 Toll-like receptor Proteins 0.000 description 40
102000002689 Toll-like receptor Human genes 0.000 description 37
239000002609 medium Substances 0.000 description 36
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 32
239000011780 sodium chloride Substances 0.000 description 31
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 30
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 30
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 30
239000006166 lysate Substances 0.000 description 30
108090000623 proteins and genes Proteins 0.000 description 28
238000000108 ultra-filtration Methods 0.000 description 28
241000894006 Bacteria Species 0.000 description 27
239000002585 base Substances 0.000 description 27
239000008213 purified water Substances 0.000 description 27
230000000694 effects Effects 0.000 description 26
241000699666 Mus <mouse, genus> Species 0.000 description 25
238000011534 incubation Methods 0.000 description 25
102000004169 proteins and genes Human genes 0.000 description 25
238000001471 micro-filtration Methods 0.000 description 24
235000018102 proteins Nutrition 0.000 description 24
239000000556 agonist Substances 0.000 description 23
150000008574 D-amino acids Chemical class 0.000 description 22
238000003756 stirring Methods 0.000 description 22
238000002474 experimental method Methods 0.000 description 21
239000000126 substance Substances 0.000 description 21
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 20
102100024333 Toll-like receptor 2 Human genes 0.000 description 20
239000003513 alkali Substances 0.000 description 20
239000008103 glucose Substances 0.000 description 20
239000001963 growth medium Substances 0.000 description 20
238000001914 filtration Methods 0.000 description 19
238000000338 in vitro Methods 0.000 description 18
239000012141 concentrate Substances 0.000 description 17
239000000725 suspension Substances 0.000 description 17
238000003556 assay Methods 0.000 description 16
210000002421 cell wall Anatomy 0.000 description 16
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 15
102000004890 Interleukin-8 Human genes 0.000 description 15
108090001007 Interleukin-8 Proteins 0.000 description 15
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 15
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 15
239000001110 calcium chloride Substances 0.000 description 15
229910001628 calcium chloride Inorganic materials 0.000 description 15
229910000365 copper sulfate Inorganic materials 0.000 description 15
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 15
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 15
229930195712 glutamate Natural products 0.000 description 15
FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 15
229910052751 metal Inorganic materials 0.000 description 15
239000002184 metal Substances 0.000 description 15
239000001103 potassium chloride Substances 0.000 description 15
235000011164 potassium chloride Nutrition 0.000 description 15
239000001632 sodium acetate Substances 0.000 description 15
235000017281 sodium acetate Nutrition 0.000 description 15
235000017557 sodium bicarbonate Nutrition 0.000 description 15
229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
238000012360 testing method Methods 0.000 description 15
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 15
229910000368 zinc sulfate Inorganic materials 0.000 description 15
229960001763 zinc sulfate Drugs 0.000 description 15
229920001451 polypropylene glycol Polymers 0.000 description 14
239000006228 supernatant Substances 0.000 description 14
102000004127 Cytokines Human genes 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 13
238000000605 extraction Methods 0.000 description 13
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
239000002253 acid Substances 0.000 description 12
235000008504 concentrate Nutrition 0.000 description 12
239000007788 liquid Substances 0.000 description 12
239000000463 material Substances 0.000 description 12
239000012528 membrane Substances 0.000 description 12
210000004988 splenocyte Anatomy 0.000 description 12
230000001954 sterilising effect Effects 0.000 description 12
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 10
102100039360 Toll-like receptor 4 Human genes 0.000 description 10
238000005273 aeration Methods 0.000 description 10
239000006285 cell suspension Substances 0.000 description 10
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 10
230000005484 gravity Effects 0.000 description 10
210000000987 immune system Anatomy 0.000 description 10
239000004615 ingredient Substances 0.000 description 10
238000004659 sterilization and disinfection Methods 0.000 description 10
235000000346 sugar Nutrition 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 9
102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 9
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 9
229940024606 amino acid Drugs 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 9
230000012010 growth Effects 0.000 description 9
230000028993 immune response Effects 0.000 description 9
244000005700 microbiome Species 0.000 description 9
239000006041 probiotic Substances 0.000 description 9
235000018291 probiotics Nutrition 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 8
230000004913 activation Effects 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
239000002158 endotoxin Substances 0.000 description 8
229920006008 lipopolysaccharide Polymers 0.000 description 8
230000037361 pathway Effects 0.000 description 8
239000012466 permeate Substances 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
230000000529 probiotic effect Effects 0.000 description 8
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 7
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 7
235000010469 Glycine max Nutrition 0.000 description 7
241001494479 Pecora Species 0.000 description 7
208000026935 allergic disease Diseases 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
150000001720 carbohydrates Chemical class 0.000 description 7
210000003743 erythrocyte Anatomy 0.000 description 7
239000012894 fetal calf serum Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 7
239000013642 negative control Substances 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
238000002965 ELISA Methods 0.000 description 6
244000068988 Glycine max Species 0.000 description 6
108010074328 Interferon-gamma Proteins 0.000 description 6
150000008575 L-amino acids Chemical class 0.000 description 6
108010028921 Lipopeptides Proteins 0.000 description 6
208000024777 Prion disease Diseases 0.000 description 6
102100039357 Toll-like receptor 5 Human genes 0.000 description 6
238000010306 acid treatment Methods 0.000 description 6
239000001569 carbon dioxide Substances 0.000 description 6
229910002092 carbon dioxide Inorganic materials 0.000 description 6
238000009472 formulation Methods 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
244000144972 livestock Species 0.000 description 6
230000036961 partial effect Effects 0.000 description 6
210000004989 spleen cell Anatomy 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 5
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 5
101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 5
102100037850 Interferon gamma Human genes 0.000 description 5
108090001030 Lipoproteins Proteins 0.000 description 5
102000004895 Lipoproteins Human genes 0.000 description 5
239000001888 Peptone Substances 0.000 description 5
108010080698 Peptones Proteins 0.000 description 5
PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
239000000427 antigen Substances 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
239000012634 fragment Substances 0.000 description 5
150000004676 glycans Chemical class 0.000 description 5
230000036039 immunity Effects 0.000 description 5
230000002779 inactivation Effects 0.000 description 5
239000003446 ligand Substances 0.000 description 5
235000019319 peptone Nutrition 0.000 description 5
229920001282 polysaccharide Polymers 0.000 description 5
239000005017 polysaccharide Substances 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
230000004044 response Effects 0.000 description 5
230000028327 secretion Effects 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000007858 starting material Substances 0.000 description 5
230000004936 stimulating effect Effects 0.000 description 5
208000035473 Communicable disease Diseases 0.000 description 4
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 4
241000607142 Salmonella Species 0.000 description 4
239000013566 allergen Substances 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000003042 antagnostic effect Effects 0.000 description 4
230000002924 anti-infective effect Effects 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000011026 diafiltration Methods 0.000 description 4
238000004020 luminiscence type Methods 0.000 description 4
230000002101 lytic effect Effects 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
230000003204 osmotic effect Effects 0.000 description 4
244000045947 parasite Species 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
238000006722 reduction reaction Methods 0.000 description 4
238000012216 screening Methods 0.000 description 4
241000894007 species Species 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
235000013311 vegetables Nutrition 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
108010079458 CBLB502 Proteins 0.000 description 3
FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
208000018522 Gastrointestinal disease Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000003816 Interleukin-13 Human genes 0.000 description 3
108090000176 Interleukin-13 Proteins 0.000 description 3
229920002274 Nalgene Polymers 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
239000004695 Polyether sulfone Substances 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
206010040047 Sepsis Diseases 0.000 description 3
239000012190 activator Substances 0.000 description 3
238000003349 alamar blue assay Methods 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
230000006037 cell lysis Effects 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000002949 hemolytic effect Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
239000012678 infectious agent Substances 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
229960002329 methacholine Drugs 0.000 description 3
210000005087 mononuclear cell Anatomy 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
230000008723 osmotic stress Effects 0.000 description 3
229920006393 polyether sulfone Polymers 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000011148 porous material Substances 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
238000002731 protein assay Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
238000011084 recovery Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000004448 titration Methods 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
241000272517 Anseriformes Species 0.000 description 2
241000271566 Aves Species 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
229930195711 D-Serine Natural products 0.000 description 2
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 2
229930028154 D-arginine Natural products 0.000 description 2
WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
229930182847 D-glutamic acid Natural products 0.000 description 2
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 2
229930195721 D-histidine Natural products 0.000 description 2
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
229930182818 D-methionine Natural products 0.000 description 2
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 2
229930182832 D-phenylalanine Natural products 0.000 description 2
206010011906 Death Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
241000222722 Leishmania <genus> Species 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
108010013639 Peptidoglycan Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
208000035415 Reinfection Diseases 0.000 description 2
241000219061 Rheum Species 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
208000006731 Salmonella Food Poisoning Diseases 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
238000010817 Wright-Giemsa staining Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
210000004979 bone marrow derived macrophage Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
239000000919 ceramic Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
239000006059 cover glass Substances 0.000 description 2
230000009615 deamination Effects 0.000 description 2
238000006481 deamination reaction Methods 0.000 description 2
230000034994 death Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
208000010643 digestive system disease Diseases 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229950009493 entolimod Drugs 0.000 description 2
239000012467 final product Substances 0.000 description 2
235000013373 food additive Nutrition 0.000 description 2
239000002778 food additive Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000004519 grease Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000009434 installation Methods 0.000 description 2
230000031261 interleukin-10 production Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
230000002934 lysing effect Effects 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
150000002772 monosaccharides Chemical class 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
239000000843 powder Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
229920002477 rna polymer Polymers 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
230000011664 signaling Effects 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000003068 static effect Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000005199 ultracentrifugation Methods 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241001655328 Bifidobacteriales Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241001631457 Cannula Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
-1 D-asbaragin Chemical compound 0.000 description 1
ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 1
229930195715 D-glutamine Natural products 0.000 description 1
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
229930182819 D-leucine Natural products 0.000 description 1
VJDOAZKNBQCAGE-LMVFSUKVSA-N D-ribitol 5-phosphate Chemical compound OC[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O VJDOAZKNBQCAGE-LMVFSUKVSA-N 0.000 description 1
AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
229930182822 D-threonine Natural products 0.000 description 1
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
229930195709 D-tyrosine Natural products 0.000 description 1
KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
229930182831 D-valine Natural products 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
239000004278 EU approved seasoning Substances 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
101150067401 Ly96 gene Proteins 0.000 description 1
102100033446 Lymphocyte antigen 96 Human genes 0.000 description 1
IMSOBGJSYSFTKG-PKPIPKONSA-N Lysinoalanine Chemical compound OC(=O)[C@@H](N)CCCCNCC(N)C(O)=O IMSOBGJSYSFTKG-PKPIPKONSA-N 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
108010057466 NF-kappa B Proteins 0.000 description 1
102000003945 NF-kappa B Human genes 0.000 description 1
108700038250 PAM2-CSK4 Proteins 0.000 description 1
229920006926 PFC Polymers 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
102100038567 Properdin Human genes 0.000 description 1
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
101900195698 Salmonella typhimurium Flagellin Proteins 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
102000008228 Toll-like receptor 2 Human genes 0.000 description 1
108010060888 Toll-like receptor 2 Proteins 0.000 description 1
102100024324 Toll-like receptor 3 Human genes 0.000 description 1
108010060812 Toll-like receptor 5 Proteins 0.000 description 1
102100039387 Toll-like receptor 6 Human genes 0.000 description 1
102100039390 Toll-like receptor 7 Human genes 0.000 description 1
102100033110 Toll-like receptor 8 Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000002390 adhesive tape Substances 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
230000010085 airway hyperresponsiveness Effects 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000012443 analytical study Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
238000013096 assay test Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000012297 crystallization seed Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000011978 dissolution method Methods 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
239000000428 dust Substances 0.000 description 1
229910052571 earthenware Inorganic materials 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000011194 food seasoning agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
230000036541 health Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000019734 interleukin-12 production Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000013586 microbial product Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
WZRRZVUZWWMSKH-UHFFFAOYSA-N n'-naphthalen-1-ylethane-1,2-diamine;hydrochloride Chemical compound Cl.C1=CC=C2C(NCCN)=CC=CC2=C1 WZRRZVUZWWMSKH-UHFFFAOYSA-N 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
238000011809 primate model Methods 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000007065 protein hydrolysis Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000004223 radioprotective effect Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000003134 recirculating effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
230000007017 scission Effects 0.000 description 1
208000008864 scrapie Diseases 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP2011526017A 2008-09-04 2008-09-04 ラクトバチルス属細菌の免疫調節抽出物及びその製造法と使用法 Pending JP2012502026A (ja)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2008/010350 WO2010027344A1 (en)	2008-09-04	2008-09-04	Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof

Publications (1)

Publication Number	Publication Date
JP2012502026A true JP2012502026A (ja)	2012-01-26

Family

ID=41797341

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2011526017A Pending JP2012502026A (ja)	2008-09-04	2008-09-04	ラクトバチルス属細菌の免疫調節抽出物及びその製造法と使用法

Country Status (11)

Country	Link
JP (1)	JP2012502026A (pt)
KR (1)	KR20110051268A (pt)
CN (1)	CN102143756A (pt)
AU (1)	AU2008361375B2 (pt)
BR (1)	BRPI0822997A2 (pt)
CA (1)	CA2733249A1 (pt)
IL (1)	IL211041A0 (pt)
MX (1)	MX2011002080A (pt)
RU (1)	RU2500412C2 (pt)
WO (1)	WO2010027344A1 (pt)
ZA (1)	ZA201100899B (pt)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015046407A1 (ja) *	2013-09-26	2015-04-02	雪印メグミルク株式会社	免疫疾患予防剤
JP2015535829A (ja) *	2012-09-21	2015-12-17	マッケーナ、エリザベス	天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
US9713630B2 (en)	2012-01-16	2017-07-25	Labyrinth Holdings, Llc	Compositions and methods for the treatment of hepatic diseases and disorders
WO2018221651A1 (ja) *	2017-06-01	2018-12-06	株式会社明治	チーズ風味素材の製造方法
JP2019077694A (ja) *	2013-09-26	2019-05-23	雪印メグミルク株式会社	免疫疾患予防剤
WO2019235592A1 (ja) *	2018-06-07	2019-12-12	国立大学法人金沢大学	腎障害の予防又は治療用の医薬組成物
WO2019235590A1 (ja) *	2018-06-07	2019-12-12	国立大学法人金沢大学	腎障害の予防又は治療用の医薬組成物
JP2022525177A (ja) *	2019-03-14	2022-05-11	オーエムファーマ	安定細菌抽出物を作製するプロセス及び医薬としてのその使用
JP2022174615A (ja) *	2021-05-11	2022-11-24	スノーデン株式会社	トル様受容体２結合物質の製造方法
US12268718B2 (en)	2012-01-16	2025-04-08	Labyrinth Holdings Llc	Control of cellular redox levels
JP2025530091A (ja) *	2022-09-28	2025-09-11	シンバイオテックインコーポレイテッド	共生組成物を用いたサルモネラ・チフィリウム感染症に対する方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2837751C (en) *	2011-02-02	2018-01-09	Justbio Inc.	Functional foods and beverages with synergistic properties to promote homeostasis
EP2697371B1 (en) *	2011-03-29	2016-10-19	Nestec S.A.	Lactobacillus johnsonii strain cncm i-4437, deficient in d-lactic acid production and with an improved shelf life
AU2012234193B2 (en) *	2011-03-29	2016-07-21	Nestec S. A.	Natural derivative of the Lactobacilus johnsonii strain CNCM I-1225, deficient in D-lactic acid production and with a further improved immune profile
US20130022586A1 (en)	2011-07-21	2013-01-24	James Versalovic	Production and use of bacterial histamine
US20150017208A1 (en) *	2013-07-12	2015-01-15	National Yang-Ming University	Lactic acid bacterium having immunomodulatory and anti-allergic effects
CN104886255B (zh) *	2014-03-07	2018-11-27	内蒙古伊利实业集团股份有限公司	具有缓解咽喉部炎症功效的益生菌食品组合物及食品
KR101627806B1 (ko) *	2014-06-23	2016-06-07	한국식품연구원	락토바실러스 속 균주의 면역증강 활성을 증가시키는 배양 방법
KR102335710B1 (ko)	2017-10-31	2021-12-07	(주)아모레퍼시픽	유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물
TWI731209B (zh) *	2018-01-09	2021-06-21	柯順議	益生菌組合物及其用途
CN112534043B (zh)	2018-05-09	2024-04-26	Ko生物技术有限公司	副干酪乳杆菌菌株及其用途
CN109007842A (zh) *	2018-10-29	2018-12-18	广州普维君健药业有限公司	具有防治过敏功效的益生菌组合物及其应用
CN109628359B (zh) *	2019-02-22	2021-03-02	江南大学	一株可缓解过敏性哮喘的罗伊氏乳杆菌及其应用
KR102156829B1 (ko) *	2019-02-22	2020-09-18	가톨릭대학교 산학협력단	마이크로바이옴 혼합물을 포함하는 면역 질환의 예방 및 치료용 조성물
CN110643541B (zh) *	2019-10-25	2021-08-24	江南大学	一株可调节过敏性哮喘Th2/Th1平衡的干酪乳杆菌及其应用
CN111053789A (zh) *	2019-11-26	2020-04-24	湖南营养树生物科技有限公司	调节免疫系统的方法和组合物
WO2021142514A1 (en) *	2020-01-13	2021-07-22	Monash University	Compositions and methods
CN111548961A (zh) *	2020-05-15	2020-08-18	郑州和合生物工程技术有限公司	改善过敏性疾病的益生菌组合物、益生菌组合物菌粉及制备方法，应用
US11826390B2 (en) *	2020-06-06	2023-11-28	Quorum Innovations, Llc	Materials and methods for inhibiting a viral infection, including a coronavirus infection
CN111991428A (zh) *	2020-06-12	2020-11-27	郑州和合生物工程技术有限公司	一种具有改善哮喘作用的益生菌组合物及其制备方法
CN112057479B (zh) *	2020-11-16	2021-02-12	河北一然生物科技有限公司	一种能够缓解抗生素引起腹泻的益生菌组合物
KR102424594B1 (ko) *	2020-11-30	2022-07-25	파이토지노믹스 주식회사	항염 활성 및 유해 미생물에 대한 항균 활성을 가지는 락토바실러스 퍼멘텀 okbl-l.fe 1 균주 및 이의 용도
KR20230001127A (ko)	2021-06-28	2023-01-04	농업회사법인 산청바이오진생마을 주식회사	새싹 인삼 라떼 제조방법
WO2023167563A1 (ko) *	2022-03-03	2023-09-07	한국생명공학연구원	N-카바밀-l-글루탐산을 포함하는 염증성 질환의 치료용 조성물
CN114774302B (zh) *	2022-03-09	2023-06-16	善恩康生物科技（苏州）有限公司	植物乳杆菌cqpc02在制备用于预防和/或治疗狼疮性肾炎的产品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08268899A (ja) *	1995-03-28	1996-10-15	Snow Brand Milk Prod Co Ltd	病原体感染防御剤
JP2007269737A (ja) *	2006-03-31	2007-10-18	Morinaga Milk Ind Co Ltd	インターロイキン産生調節剤、該インターロイキン産生調節剤を含む医薬組成物及び飲食品、並びにその製造方法
JP2008031153A (ja) *	2006-06-26	2008-02-14	Yakult Honsha Co Ltd	インターロイキン１０産生促進剤
JP2008545428A (ja) *	2005-05-31	2008-12-18	ザ・アイムス・カンパニー	ネコ科動物プロバイオティックであるラクトバシラス

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH532903A (fr) *	1971-06-25	1973-01-31	Nestle Sa	Procédé d'extraction de protéines à partir de cellules de microorganismes
EP1239032A1 (en) *	2001-03-02	2002-09-11	Société des Produits Nestlé S.A.	Lactic acid bacteria as agents for treating and preventing allergy
PE20030274A1 (es) *	2001-07-26	2003-05-08	Alimentary Health Ltd	Cepas de lactobacillus salivarius
RU2302458C2 (ru) *	2001-07-26	2007-07-10	Элиментери Хелс Лимитед	Пробиотический штамм lactobacillus salivarius (варианты), пробиотический препарат на их основе и способ лечения или предупреждения с использованием штаммов lactobacillus salivarius
US7025998B2 (en) *	2003-05-30	2006-04-11	Rotta Research Laboratorium S.P.A.	Phytoestrogens and probiotic for women's health
CA2557834C (en) *	2004-03-04	2012-05-22	E-L Management Corporation	Skin treatment method with lactobacillus extract

2008
- 2008-09-04 WO PCT/US2008/010350 patent/WO2010027344A1/en not_active Ceased
- 2008-09-04 JP JP2011526017A patent/JP2012502026A/ja active Pending
- 2008-09-04 AU AU2008361375A patent/AU2008361375B2/en not_active Expired - Fee Related
- 2008-09-04 CN CN2008801309602A patent/CN102143756A/zh active Pending
- 2008-09-04 RU RU2011112781/15A patent/RU2500412C2/ru not_active IP Right Cessation
- 2008-09-04 KR KR1020117007527A patent/KR20110051268A/ko not_active Ceased
- 2008-09-04 CA CA2733249A patent/CA2733249A1/en not_active Abandoned
- 2008-09-04 BR BRPI0822997-0A patent/BRPI0822997A2/pt not_active IP Right Cessation
- 2008-09-04 MX MX2011002080A patent/MX2011002080A/es not_active Application Discontinuation
2011
- 2011-02-03 IL IL211041A patent/IL211041A0/en unknown
- 2011-02-03 ZA ZA2011/00899A patent/ZA201100899B/en unknown

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08268899A (ja) *	1995-03-28	1996-10-15	Snow Brand Milk Prod Co Ltd	病原体感染防御剤
JP2008545428A (ja) *	2005-05-31	2008-12-18	ザ・アイムス・カンパニー	ネコ科動物プロバイオティックであるラクトバシラス
JP2007269737A (ja) *	2006-03-31	2007-10-18	Morinaga Milk Ind Co Ltd	インターロイキン産生調節剤、該インターロイキン産生調節剤を含む医薬組成物及び飲食品、並びにその製造方法
JP2008031153A (ja) *	2006-06-26	2008-02-14	Yakult Honsha Co Ltd	インターロイキン１０産生促進剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013026289; Ｂｉｏｃｈｅｍ．　Ｊ．Ｖｏｌ．１１３, 1969, ｐｐ．８９９-９００ *
JPN6014003789; Ｊ．Ａｇｒｉｃ．Ｆｏｏｄ　Ｃｈｅｍ．２７（３）, 1979, ｐ．５０７-５１１ *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10149869B2 (en)	2012-01-16	2018-12-11	Labyrinth Holdings, Llc	Compositions and methods for the treatment of hepatic diseases and disorders
US12268718B2 (en)	2012-01-16	2025-04-08	Labyrinth Holdings Llc	Control of cellular redox levels
US10688177B2 (en)	2012-01-16	2020-06-23	Labyrinth Holdings, Llc	Naturally-occurring CpG oligonucleotide compositions and therapeutic applications thereof
US9713630B2 (en)	2012-01-16	2017-07-25	Labyrinth Holdings, Llc	Compositions and methods for the treatment of hepatic diseases and disorders
US9931398B2 (en)	2012-01-16	2018-04-03	Labyrinth Holdings, Llc	Naturally-occurring CpG oligonucleotide compositions and therapeutic applications thereof
US11857577B2 (en)	2012-01-16	2024-01-02	Labyrinth Holdings, Llc	Compositions and methods for the treatment of hepatic diseases and disorders
US12343361B2 (en)	2012-01-16	2025-07-01	Labyrinth Holdings, Llc	Compositions and methods for the treatment of hepatic diseases and disorders
JP2015535829A (ja) *	2012-09-21	2015-12-17	マッケーナ、エリザベス	天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
WO2015046407A1 (ja) *	2013-09-26	2015-04-02	雪印メグミルク株式会社	免疫疾患予防剤
JP2015086214A (ja) *	2013-09-26	2015-05-07	雪印メグミルク株式会社	免疫疾患予防剤
JP2019077694A (ja) *	2013-09-26	2019-05-23	雪印メグミルク株式会社	免疫疾患予防剤
US11259539B2 (en)	2017-06-01	2022-03-01	Meiji Co., Ltd.	Method for producing cheese-flavored substance
WO2018221651A1 (ja) *	2017-06-01	2018-12-06	株式会社明治	チーズ風味素材の製造方法
JP2018201382A (ja) *	2017-06-01	2018-12-27	株式会社明治	チーズ風味素材の製造方法
JP2019214557A (ja) *	2018-06-07	2019-12-19	国立大学法人金沢大学	腎障害の予防又は治療用の医薬組成物
JP7364165B2 (ja)	2018-06-07	2023-10-18	国立大学法人金沢大学	腎障害の予防又は治療用の医薬組成物
JP7364166B2 (ja)	2018-06-07	2023-10-18	国立大学法人金沢大学	腎障害の予防又は治療用の医薬組成物
JP2019214558A (ja) *	2018-06-07	2019-12-19	国立大学法人金沢大学	腎障害の予防又は治療用の医薬組成物
US12220394B2 (en)	2018-06-07	2025-02-11	National University Corporation Kanazawa University	Pharmaceutical composition for prevention or treatment of kidney damage
WO2019235590A1 (ja) *	2018-06-07	2019-12-12	国立大学法人金沢大学	腎障害の予防又は治療用の医薬組成物
WO2019235592A1 (ja) *	2018-06-07	2019-12-12	国立大学法人金沢大学	腎障害の予防又は治療用の医薬組成物
JP2022525177A (ja) *	2019-03-14	2022-05-11	オーエムファーマ	安定細菌抽出物を作製するプロセス及び医薬としてのその使用
JP2022174615A (ja) *	2021-05-11	2022-11-24	スノーデン株式会社	トル様受容体２結合物質の製造方法
JP7723917B2 (ja)	2021-05-11	2025-08-15	スノーデン株式会社	トル様受容体２結合物質の製造方法
JP2025530091A (ja) *	2022-09-28	2025-09-11	シンバイオテックインコーポレイテッド	共生組成物を用いたサルモネラ・チフィリウム感染症に対する方法

Also Published As

Publication number	Publication date
CN102143756A (zh)	2011-08-03
IL211041A0 (en)	2011-04-28
WO2010027344A1 (en)	2010-03-11
CA2733249A1 (en)	2010-03-11
MX2011002080A (es)	2011-03-29
RU2011112781A (ru)	2012-10-10
AU2008361375A1 (en)	2010-03-11
BRPI0822997A2 (pt)	2015-06-23
ZA201100899B (en)	2012-05-30
KR20110051268A (ko)	2011-05-17
RU2500412C2 (ru)	2013-12-10
AU2008361375B2 (en)	2014-05-22

Legal Events

Date	Code	Title	Description
2012-09-01	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120831
2013-06-05	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130604
2013-09-05	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130904
2014-02-05	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140204
2014-05-08	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140507
2014-05-15	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140514
2014-06-05	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140604
2014-06-12	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140611
2014-09-10	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140909

Publication	Publication Date	Title
RU2500412C2 (ru)	2013-12-10	ИММУНОМОДУЛИРУЮЩИЕ ЭКСТРАКТЫ ИЗ БАКТЕРИЙ Lactobacillus И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
Sashihara et al.	2006	An analysis of the effectiveness of heat-killed lactic acid bacteria in alleviating allergic diseases
RU2599422C2 (ru)	2016-10-10	Макромолекулярный комплекс бактериального происхождения и его применение для предотвращения или лечения ревматоидного артрита
Galdeano et al.	2009	Mechanisms involved in the immunostimulation by probiotic fermented milk
JP6041458B2 (ja)	2016-12-07	消化管又は尿管の障害のための細菌抽出物及びその製造方法
KR20110082480A (ko)	2011-07-19	포유동물 체내에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
HK1044964A1 (zh)	2002-11-08	用於治療炎性疾病的雙岐桿菌
CN113747908A (zh)	2021-12-03	益生菌的治疗性微泡
US20100055082A1 (en)	2010-03-04	Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
US10857128B2 (en)	2020-12-08	Methods and compositions for treating inflammatory diseases
EP2161329A1 (en)	2010-03-10	Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
Wang et al.	2019	Lactic acid bacteria and host immunity
HK1160603A (en)	2012-08-10	Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
TW201010711A (en)	2010-03-16	Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
Maldonado Galdeano et al.	2009	Mechanisms involved in the immunostimulation by probiotic fermented milk
AU2013200193B2 (en)	2015-04-23	Bacterial extract for digestive or urinary tract disorders and process for its preparation
Donkor et al.	2010	Probiotics and immunomodulation
AL-Greti	2016	Study of Immune Adjuvant Acti Laboratory Animals
Підгорський et al.	2011	EFFECTS OF DRY ENZYMATIC LYSATE DEL-IMMUNE V® ON CYTOKINE PRODUCTION IN THE EXPERIMENTAL MODELS
Tellez Garay	2009	Characterization of immuno active peptides present in cell free preparations obtained from milk fermented by Lactobacillus helveticus
Garay	2010	Characterization of immuno active peptides present in cell free preparations obtained from milk fermented by Lactobacillus helveticus.
O'Mahony	2017	Biology of the Microbiome
Haileselassie	2013	THE INFLUENCE OF LACTOBACILLI AND STAPHYLOCOCCUS AUREUS ON IMMUNE RESPONSIVENESS IN VITRO
AU2008253830A1 (en)	2008-11-27	Probiotic bacterium